NasdaqGS:IONSBiotechs
A Fresh Look at Ionis Pharmaceuticals (IONS) Valuation After Positive Olezarsen Trial and DAWNZERA Regulatory Update
Ionis Pharmaceuticals (IONS) recently grabbed investor attention thanks to positive Phase 3 results for olezarsen, along with a favorable regulatory opinion in Europe for DAWNZERA to prevent hereditary angioedema attacks.
See our latest analysis for Ionis Pharmaceuticals.
Ionis Pharmaceuticals has been on a tear lately, with major clinical wins and a green light from European regulators for DAWNZERA helping fuel a dramatic rally. Over the past year, shares have delivered a remarkable 123.7%...